4th Quarter - Report

NATIONAL KIDNEY FOUNDATION for NATIONAL KIDNEY FOUNDATION

Firm
Client
Income
—
Expenses
$95,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Budget/Appropriations BUD

FY 2025 Appropriations for CDC Chronic Kidney Disease Initiative. FY 2025 Appropriations for kidney disease research at the National Institute of Diabetes and Digestive and Kidney Diseases. FY 2025 Appropriations for the National Heart, Lung and Blood Institute. FY 2025 Appropriations under the Health Resources and Services Administration, with emphasis on organ donation and transplant activities. FY 2025 Appropriations for the Indian Health Service.

LobbyistCovered position, as disclosed
LAUREN DREW —
TROY ZIMMERMAN —

Contacted: Natl Institutes of Health (NIH); SENATE; HOUSE OF REPRESENTATIVES; Centers For Disease Control & Prevention (CDC); Indian Health Service; Health Resources & Services Administration (HRSA); Health & Human Services, Dept of (HHS)

Health Issues HCR

H.R. 2923 and S. 1384, "Living Donor Protection Act of 2023", to prohibit discrimination in the issuing, pricing and benefits amount of life, disability, or long-term care insurance policies for living organ donors. H.R. 2544 (P.L. 118-14), "Securing the U.S. Organ Procurement and Transplantation Network Act." H.R. 6020, "Honor Our Living Donors Act." H.R. 6171, "Living Organ Donor Tax Credit Act." H.R. 10282, "Expanding Support for Living Donors Act." Initiatives and activities to increase, improve, and facilitate organ donation and transplantation, including equity in transplant access and data standardization initiatives. Implementation of HHS Advancing American Kidney Health Initiative. Activities to address COVID-19 and the needs of people with kidney disease. Activities to address ethnic, racial and social disparities in health and access to care. Telemedicine and telehealth access. Affordable Care Act access, utilization and benefits, including H.R. 1692 "Health Care Affordability Act." Prescription drug pricing and access. Comments on National Institute of Minority Health and Health Disparities draft Strategic Plan. Comment on information collection request on Process Data for the Organ Donation and Transplantation Network (OPTN). Comments on revised HIV Organ Policy Equity Act Safeguards and Research Criteria.

LobbyistCovered position, as disclosed
LAUREN DREW —
MIRIAM ELIZABETH GODWIN —
MORGAN REID —
JESSE ROACH —
TROY ZIMMERMAN —

Contacted: SENATE; Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; Centers For Disease Control & Prevention (CDC); Food & Drug Administration (FDA); Natl Institutes of Health (NIH); Health Resources & Services Administration (HRSA)

Bills named: H.R. 2544 (118th), H.R. 10282 (118th), H.R. 1692 (118th), H.R. 6171 (118th), H.R. 6020 (118th), S. 1384 (118th), H.R. 2923 (118th)

Medicare/Medicaid MMM

H.R. 8075, Improving Access to Home Dialysis Act. S. 2407, H.R. 4818, the "Treat and Reduce Obesity Act" S. 1832, H.R. 3842, "Expanding Access to Diabetes Self-Management Training Act" H.R. 5074, S. 4510 "Kidney PATIENT Act of 2023" H.R. 6860, S. 5018 "Restore Protections for Dialysis Patients Act." H.R. 7856, S. 4094, "PREVENT Diabetes Act." Inflation Reduction Act Medicare drug pricing, including Medicare Part D Redesign Program Guidance. Support for Medicare Part D Protected Classes coverage. Kidney patient health and management under Medicare Advantage. Medicare activities and coverage for COVID-19 patients. Protect Medicaid eligibility. Activities regarding implementation of HHS Advancing American Kidney Health Initiative. Activities to address rural health access and quality. Comments on Medicare $2 Drug List Model RFI.

LobbyistCovered position, as disclosed
LAUREN DREW —
MIRIAM ELIZABETH GODWIN —
MORGAN REID —
JESSE ROACH —
TROY ZIMMERMAN —

Contacted: Health & Human Services, Dept of (HHS); Centers For Medicare and Medicaid Services (CMS); SENATE; HOUSE OF REPRESENTATIVES

Bills named: S. 4510 (118th), H.R. 8075 (118th), H.R. 6860 (118th), H.R. 4818 (118th), S. 2407 (118th), S. 1832 (118th), H.R. 5074 (118th), H.R. 3842 (118th), H.R. 7856 (118th), S. 4094 (118th), S. 5018 (118th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.